BAYN has been the subject of a number of other research reports. Nord/LB reiterated a neutral rating on shares of Bayer in a report on Wednesday, December 27th. DZ Bank reiterated a buy rating on shares of Bayer in a report on Monday, December 11th. UBS Group reiterated a buy rating on shares of Bayer in a report on Monday, January 15th. Barclays set a €105.00 ($129.63) target price on Bayer and gave the stock a sell rating in a report on Monday, November 6th. Finally, Deutsche Bank set a €125.00 ($154.32) target price on Bayer and gave the stock a buy rating in a report on Friday, January 19th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the stock. Bayer has a consensus rating of Buy and an average price target of €121.71 ($150.26).
Bayer (FRA:BAYN) traded up €1.15 ($1.42) on Friday, hitting €98.54 ($121.65). 3,334,206 shares of the company were exchanged. Bayer has a 1-year low of €93.30 ($115.19) and a 1-year high of €123.82 ($152.86). The company has a market cap of $81,520.00 and a PE ratio of 23.30.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/markets/bayers-bayn-buy-rating-reiterated-at-citigroup/1888337.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.